secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001213900-25-088792
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16
--------------------------------------------------------------------------------

- All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).
- High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.
- Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.
- Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.
- Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/0001213900-25-088792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/ea0257842-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-088792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer